|
|
Summary ToggleTherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD and Afaxys Enter Into Agreement to Expand Access to ANNOVERA® in the U.S. Public Health Sector
|
|
|
|
Summary ToggleTherapeuticsMD to Report Fourth Quarter 2019 Results on February 20, 2020
|
|
|
|
Summary ToggleTherapeuticsMD Announces Submission of New Drug Application Prior Approval Efficacy Supplement to the U.S. Food and Drug Administration for Lower Dose of BIJUVA®
|
|
|
|
Summary ToggleTherapeuticsMD, an Innovative Women’s Healthcare Company, and PlushCare, a Virtual Health Platform, Announce Enhanced Access to Women’s Health Products
|
|
|
|
Summary ToggleTherapeuticsMD Announces Participation at the JP Morgan Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD Announces Amendment to Term Loan Financing Facility with TPG Sixth Street Partners
|
|
|
|
Summary ToggleKnight and TherapeuticsMD Announce Filing of New Drug Submission for BIJUVA® in Canada
|
|
|
|
Summary ToggleTherapeuticsMD Announces Participation at the Stifel 2019 Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD Announces Third Quarter 2019 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD to Report Third Quarter 2019 Results on November 6, 2019
|
|
|
|
Summary ToggleKnight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada
|
|
|
|
Summary ToggleTherapeuticsMD Announces Closing of Its Underwritten Public Offering of Common Stock
|
|
|
|
Summary ToggleTherapeuticsMD Announces Pricing of Its Underwritten Public Offering of 26 Million Shares of Common Stock
|
|
|
|
Summary ToggleTherapeuticsMD Announces Proposed Underwritten Public Offering of 22 Million Shares of Common Stock
|
|
|
|
Summary ToggleTherapeuticsMD Announces Estimated Third Quarter 2019 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD Announces Presentations on ANNOVERA™ at the 2019 Annual Meeting of the American Society for Reproductive Medicine
|
|
|
|
Summary ToggleTherapeuticsMD Vice President of Business Development Named Finalist in 16th Annual Stevie® Awards for Women in Business
|
|
|
|
Summary ToggleTherapeuticsMD Announces Participation at the 2019 Cantor Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD Announces Multiple Presentations Related to IMVEXXY® and BIJUVA® at the 2019 Annual Meeting of the North American Menopause Society
|
|
|
|
Summary ToggleTherapeuticsMD Announces Second Quarter 2019 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD to Report Second Quarter 2019 Results on August 6, 2019
|
|
|
|
Summary ToggleTherapeuticsMD to Host Investor and Analyst Day Today
|
|
|
|
Summary ToggleTherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA™ and IMVEXXY® Outside the United States
|
|
|
|
Summary ToggleTherapeuticsMD to Host Investor and Analyst Day on June 10, 2019 in New York City
|
|
|
|
Summary ToggleTherapeuticsMD Announces Participation at the Bank of America Merrill Lynch 2019 Health Care Conference
|
|
|
|
Summary ToggleTherapeuticsMD Announces First Quarter 2019 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD Presented New Research at the American College of Obstetricians and Gynecologists 2019 Annual Meeting that Explores How Women’s Menopausal Symptoms Affect Men
|
|
|
|
Summary ToggleTherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the American College of Obstetricians and Gynecologists 2019 Annual Meeting
|
|
|
|
Summary ToggleTherapeuticsMD to Report First Quarter 2019 Results on May 6, 2019
|
|
|
|
Summary ToggleTherapeuticsMD Closes $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
|
|
|
|
Summary ToggleTherapeuticsMD Signs Binding Commitment Letter for $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
|
|
|
|
Summary ToggleTherapeuticsMD Announces Commercial Availability of BIJUVA™ in the U.S.
|
|
|
|
Summary ToggleTherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the Endocrine Society 2019 Annual Meeting
|
|
|
|
Summary ToggleTherapeuticsMD Announces Oral Presentations on BIJUVA and ANNOVERA, and Poster Presentations Related to Menopause Symptoms and Treatments at 2019 ISSWSH/ISSM Joint Meeting
|
|
|
|
Summary ToggleTherapeuticsMD Announces Participation in Two Upcoming Investor Conferences
|
|
|
|
Summary ToggleTherapeuticsMD Announces Fourth Quarter and Full-Year 2018 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD to Report Fourth Quarter and Full Year 2018 Results on February 21, 2019
|
|
|
|
Summary ToggleTherapeuticsMD Announces Participation at 37th Annual J.P. Morgan Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD Announces Participation in Three Upcoming Investor Conferences
|
|
|
|
Summary ToggleTherapeuticsMD Announces Third Quarter 2018 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD to Report Third Quarter 2018 Financial Results on November 7, 2018
|
|
|
|
Summary ToggleTherapeuticsMD Announces FDA Approval of TX-001HR: BIJUVA™ (Estradiol and Progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause
|
|
|
|
Summary ToggleTherapeuticsMD Announces Multiple Presentations Related to Imvexxy™ and TX-001HR at the 2018 Annual Meeting of the North American Menopause Society
|
|
|
|
Summary ToggleTherapeuticsMD Enters Into Label Discussions for TX-001HR
|
|
|
|
Summary ToggleTherapeuticsMD to Present at 2018 Cantor Global Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD Announces the FDA has Granted AnnoveraTM Marketing Exclusivity as a New Chemical Entity
|
|
|
|
Summary ToggleTherapeuticsMD Announces Commercial Availability of Imvexxy™ 4 mcg
|
|
|
|
Summary ToggleTherapeuticsMD to Present at 13th Annual Wells Fargo Securities Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD Announces FDA Approval of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control
|
|
|
|
Summary ToggleTherapeuticsMD Announces Closing of its Underwritten Public Offering and Concurrent Registered Direct Offering of Common Stock
|
|
|
|
Summary ToggleTherapeuticsMD Announces Pricing of Its Underwritten Public Offering and Concurrent Registered Direct Offering for Aggregate Gross Proceeds of $85 Million
|
|
|
|
Summary ToggleTherapeuticsMD Licenses Population Council’s Novel Segesterone Acetate/ Ethinyl Estradiol One-Year Vaginal Contraceptive System
|
|
|
|
Summary ToggleKnight Therapeutics and TherapeuticsMD Announce Strategic Partnership
|
|
|
|
Summary ToggleTherapeuticsMD Announces Proposed $65 Million Underwritten Public Offering and Concurrent $20 Million Registered Direct Offering of Common Stock
|
|
|
|
Summary ToggleTherapeuticsMD Announces Second Quarter 2018 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD to Report Second Quarter 2018 Financial Results on July 30, 2018
|
|
|
|
Summary ToggleTherapeuticsMD Announces Draw Down of $75 Million Under Term Loan with MidCap Financial
|
|
|
|
Summary ToggleTherapeuticsMD to Present at Goldman Sachs 39th Annual Global Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD Announces Multiple Presentations at the International Menopause Society’s 16th World Congress
|
|
|
|
Summary ToggleTherapeuticsMD to Present at Jefferies 2018 Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD Announces Clinical Abstract at the 2018 ASCO Annual Meeting
|
|
|
|
Summary ToggleTherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY™ (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom of VVA, due to Menopause
|
|
|
|
Summary ToggleTherapeuticsMD Comments on Media Reports Regarding TX-004HR
|
|
|
|
Summary ToggleTherapeuticsMD Announces Investor and Analyst Day on June 4
|
|
|
|
Summary ToggleTherapeuticsMD Announces First Quarter 2018 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD to Host First Quarter Financial Results Conference Call and Webcast on May 3
|
|
|
|
Summary ToggleTherapeuticsMD Enters Into Label Negotiations for TX-004HR
|
|
|
|
Summary ToggleTherapeuticsMD Announces Expansion of Board of Directors
|
|
|
|
Summary ToggleTherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR
|
|
|
|
Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
|
|
|
|
Summary ToggleTherapeuticsMD Announces Fourth Quarter and Full Year 2017 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD to Host Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast on February 20
|
|
|
|
Summary ToggleTherapeuticsMD Announces Presentation at 36th Annual J.P. Morgan Healthcare Conference on January 10
|
|
|
|
Summary ToggleTherapeuticsMD Announces Submission of New Drug Application for TX-001HR
|
|
|
|
Summary ToggleTherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
|
|
|
|
Summary ToggleTherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR
|
|
|
|
Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
|
|
|
|
Summary ToggleTherapeuticsMD Announces Third Quarter 2017 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR
|
|
|
|
Summary ToggleTherapeuticsMD to Host TX-004HR Regulatory Update and Third Quarter Financial Results Conference Call and Webcast on November 6
|
|
|
|
Summary ToggleTherapeuticsMD Announces Multiple Presentations Related to TX-004HR and TX-001HR at NAMS 2017
|
|
|
|
Summary ToggleTherapeuticsMD Announces Closing of Common Stock Offering
|
|
|
|
Summary ToggleTherapeuticsMD Announces Pricing of Common Stock Offering
|
|
|
|
Summary ToggleTherapeuticsMD Announces Public Offering of 12.4 Million Shares of Common Stock
|
|
|
|
Summary ToggleTherapeuticsMD Announces Move to Nasdaq Global Select Market
|
|
|
|
Summary ToggleTherapeuticsMD Announces Submission of Additional Endometrial Safety Information to the New Drug Application for TX-004HR
|
|
|
|
Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
|
|
|
|
Summary ToggleTherapeuticsMD Announces Publication of Manuscript on the Women’s Health Initiative Observational Study of Vaginal Estrogen Use in Postmenopausal Women
|
|
|
|
Summary ToggleTherapeuticsMD Provides TX-004HR Regulatory Update
|
|
|
|
Summary ToggleTherapeuticsMD Announces Second Quarter 2017 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD to Host Second Quarter Financial Results Conference Call and Webcast on August 3
|
|
|
|
Summary ToggleTherapeuticsMD Provides TX-004HR Regulatory Update
|
|
|
|
Summary ToggleTherapeuticsMD Announces Presentation at Jefferies 2017 Healthcare Conference on June 8
|
|
|
|
Summary ToggleTherapeuticsMD Announces Presentation at Bank of America Merrill Lynch 2017 Healthcare Conference on May 16
|
|
|
|
Summary ToggleTherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application
|
|
|
|
Summary ToggleTherapeuticsMD to Host TX-004HR Regulatory Update Conference Call and Webcast on May 8
|
|
|
|
Summary ToggleTherapeuticsMD Announces First Quarter 2017 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD Provides Additional Information on TX-004HR Regulatory Update
|
|
|
|
Summary ToggleTherapeuticsMD Provides TX-004HR Regulatory Update
|
|
|
|
Summary ToggleTherapeuticsMD Presents Positive Phase 3 Data in Two Presentations for TX-001HR at ENDO 2017
|
|
|
|
Summary ToggleTherapeuticsMD Announces Presentation at the Oppenheimer 27th Annual Healthcare Conference on March 22
|
|
|
|
Summary ToggleTherapeuticsMD Announces Presentation at Cowen and Company 37th Annual Healthcare Conference on March 7
|
|
|
|
Summary ToggleTherapeuticsMD Announces Fourth Quarter and Full-Year 2016 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD Announces Webcast of Investor Day on March 1
|
|
|
|
Summary ToggleTherapeuticsMD to Host Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast on February 23
|
|
|
|
Summary ToggleTherapeuticsMD Announces Investor Day on March 1
|
|
|
|
Summary ToggleTherapeuticsMD Announces Publication of Two Manuscripts on the Rejoice Trial for TX-004HR in Leading Peer-Reviewed Medical Journal
|
|
|
|
Summary ToggleTherapeuticsMD to Present at 35th Annual J.P. Morgan Healthcare Conference on January 11
|
|
|
|
Summary ToggleTherapeuticsMD Announces Participation in 2016 BioFlorida Conference
|
|
|
|
Summary ToggleTherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR
|
|
|
|
Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
|
|
|
|
Summary ToggleTherapeuticsMD Expands Commercial and Business Development Leadership
|
|
|
|
Summary ToggleTherapeuticsMD Announces Third Quarter 2016 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD to Host Third Quarter Financial Results Conference Call and Webcast on November 3
|
|
|
|
Summary ToggleTherapeuticsMD Announces Multiple Presentations Related to Yuvvexy™ (TX-004HR) at Two Upcoming Medical Conferences
|
|
|
|
Summary ToggleTherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy™ (TX-004HR)
|
|
|
|
Summary ToggleTherapeuticsMD Announces Second Quarter 2016 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD to Host Second Quarter Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD Announces New Drug Application Submission for Yuvvexy™ (TX-004HR)
|
|
|
|
Summary ToggleTherapeuticsMD Announces Filing Timeline for Yuvvexy (TX-004HR) New Drug Application
|
|
|
|
Summary ToggleTherapeuticsMD Announces New Innovation in Compliance Packaging for Prenatal Vitamins
|
|
|
|
Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
|
|
|
|
Summary ToggleTherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial
|
|
|
|
Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
|
|
|
|
Summary ToggleTherapeuticsMD Announces First Quarter 2016 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD to Host First Quarter 2016 Financial Results Conference Call and Webcast May 3
|
|
|
|
Summary ToggleTherapeuticsMD Presents Detailed Results from Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy (VVA) at ENDO 2016
|
|
|
|
Summary ToggleTherapeuticsMD to Present Data from Phase 3 Rejoice Trial at Upcoming Investor & Medical Conferences
|
|
|
|
Summary ToggleTherapeuticsMD Announces Fourth Quarter and Full Year 2015 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD Announces Poster Presentations at International Society for the Study of Women’s Sexual Health Annual Meeting
|
|
|
|
Summary ToggleTherapeuticsMD to Host Fourth Quarter and Year End 2015 Financial Results
|
|
|
|
Summary ToggleVitaMedMD Launches VitaTrue™, the First Certified Vegan and Kosher Prescription Prenatal Multivitamin
|
|
|
|
Summary ToggleTherapeuticsMD to Present at Noble Financial Capital Markets’ NobleCon12
|
|
|
|
Summary ToggleTherapeuticsMD Announces Closing of Common Stock Offering
|
|
|
|
Summary ToggleTherapeuticsMD Announces Pricing of $125 Million Common Stock Offering
|
|
|
|
Summary ToggleTherapeuticsMD Announces $125 Million Offering of Common Stock
|
|
|
|
Summary ToggleTherapeuticsMD Announces Positive Top-Line Results from its Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy (VVA) Treated with 25 mcg, 10 mcg or 4 mcg of TX-004HR
|
|
|
|
Summary ToggleTherapeuticsMD to Present at Stifel 2015 Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD Announces Third Quarter 2015 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD to Host Third Quarter 2015 Financial Results Conference Call and Webcast November 4
|
|
|
|
Summary ToggleTherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate
|
|
|
|
Summary ToggleMenopausal Women Experiencing Distressing Pain During Sex Suffer Due to Misperceptions
|
|
|
|
Summary ToggleTherapeuticsMD Announces Presentations at The North American Menopause Society 2015 Annual Meeting
|
|
|
|
Summary ToggleTherapeuticsMD Announces Second Quarter 2015 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD receives patent allowance for VVA candidate TX-004HR
|
|
|
|
Summary ToggleTherapeuticsMD to Host Second Quarter 2015 Financial Results Conference Call and Webcast August 6
|
|
|
|
Summary ToggleTherapeuticsMD Announces Pricing of Common Stock Offering
|
|
|
|
Summary ToggleTherapeuticsMD Completes Enrollment in The Rejoice Trial, a Phase 3 Clinical Trial of TX-004HR (estradiol in VagiCap™)
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. to participate in upcoming investor conferences
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. to participate in upcoming investor conferences
|
|
|
|
Summary ToggleTherapeuticsMD Inc. to present at upcoming investor conferences
|
|
|
|
Summary ToggleTherapeuticsMD announces first quarter 2015 financial results
|
|
|
|
Summary ToggleNew data on compounded prescription practices show differences among medical specialties
|
|
|
|
Summary ToggleTherapeuticsMD to host first quarter 2015 financial results conference call and webcast May 5
|
|
|
|
Summary ToggleTherapeuticsMD appoints biopharmaceutical senior executives Angus C. Russell and J. Martin Carroll as independent directors
|
|
|
|
Summary ToggleTherapeuticsMD announces fourth quarter and full-year 2014 financial results
|
|
|
|
Summary TogglePhysicians’ visual assessments correlate with objective measurements of postmenopausal VVA patients treated with TX-004HR VagiCapTM
|
|
|
|
Summary TogglePoster: Menopausal Hormone Therapy (MHT) Usage: FDA-Approved MHT Has Decreased While Compounded Non-FDA-Approved MHT Has Increased
|
|
|
|
Summary TogglePoster: Vaginal Physical Examination Correlates with Vaginal Epithelial Cells and pH and Can be Used to Assess Treatment Efficacy
|
|
|
|
Summary ToggleTherapeuticsMD to host fourth quarter, full-year 2014 financial results conference call and webcast
|
|
|
|
Summary ToggleSurvey shows postmenopausal women with VVA reported improved satisfaction and quality of life with VagiCapTM investigational local estrogen treatment
|
|
|
|
Summary ToggleTherapeuticsMD announces pricing of common stock offering
|
|
|
|
Summary ToggleTherapeuticsMD Announces Offering of Common Stock
|
|
|
|
Summary ToggleTherapeuticsMD receives five new patent allowances, further strengthens IP assets
|
|
|
|
Summary ToggleTherapeuticsMD ranks No. 1 among Florida companies in Deloitte Technology Fast 500
|
|
|
|
Summary ToggleTherapeuticsMD Inc. to present at the Stifel Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD announces third quarter financial results
|
|
|
|
Summary ToggleTherapeuticsMD to host third quarter 2014 financial results conference call and webcast November 6
|
|
|
|
Summary ToggleTherapeuticsMD announces oral presentation of positive phase 2 and bioavailability data on TX-004HR (VagiCapTM)
|
|
|
|
Summary ToggleTherapeuticsMD Inc. granted two new patents
|
|
|
|
Summary ToggleTherapeuticsMD begins phase 3 clinical trial of TX-004HR
|
|
|
|
Summary ToggleTherapeuticsMD announces second quarter 2014 financial results
|
|
|
|
Summary ToggleTherapeuticsMD to hold second quarter 2014 financial results conference call and webcast on August 6
|
|
|
|
Summary ToggleTherapeuticsMD announces pricing of offering of common stock
|
|
|
|
Summary ToggleTherapeuticsMD announces $40 million offering of common stock
|
|
|
|
Summary ToggleTherapeuticsMD to present at JMP HealthCare Conference
|
|
|
|
Summary ToggleTherapeuticsMD announces 2014 Investor Day webcast on June 16
|
|
|
|
Summary ToggleTherapeuticsMD announces release of RediChew and Prena1 Chew
|
|
|
|
Summary ToggleTherapeuticsMD to present at Jefferies 2014 HealthCare Conference
|
|
|
|
Summary ToggleTherapeuticsMD reports first quarter 2014 results
|
|
|
|
Summary ToggleTherapeuticsMD to present the design of its REPLENISH Trial at the IMS 14th World Congress
|
|
|
|
Summary ToggleTherapeuticsMD to present at Bank of America Merrill Lynch 2014 Health Care Conference
|
|
|
|
Summary ToggleTherapeuticsMD to host conference call and live audio webcast to disclose first quarter financial results
|
|
|
|
Summary ToggleTherapeuticsMD reports positive results of rabbit irritation study
|
|
|
|
Summary ToggleBocaGreenMD launches PRENA1 PEARL
|
|
|
|
Summary ToggleTherapeuticsMD announces pricing of secondary offering
|
|
|
|
Summary ToggleVitaMedMD launches vitaPearl
|
|
|
|
Summary ToggleTherapeuticsMD announces launch of secondary offering
|
|
|
|
Summary ToggleTherapeuticsMD reports fourth quarter and full-year 2013 results
|
|
|
|
Summary ToggleTherapeuticsMD to Present at Cowen & Co. 34th Annual Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD announces conference call to disclose 2013 year-end results
|
|
|
|
Summary ToggleTherapeuticsMD reports positive PK sudy results for its estradiol VagiCap™ (TX-004HR)
|
|
|
|
Summary ToggleTherapeuticsMD initiates phase 3 clinical trial of its progesterone candidate (TX-002HR) for treatment of secondary amenorrhea
|
|
|
|
Summary ToggleTherapeuticsMD announces issuance of U.S. patent covering TX-001HR
|
|
|
|
Summary ToggleTherapeuticsMD announces 50th site for phase 3 clinical trial of TX-001HR
|
|
|
|
Summary ToggleTherapeuticsMD names Randall S. Stanicky to Board of Directors
|
|
|
|
Summary ToggleTherapeuticsMD receives notice of allowance for patient covering platform technology of oral combination bioidentical 17β-estradiol and progesterone
|
|
|
|
Summary ToggleTherapeuticsMD appoints Joel S. Krasnow, M.D. as Chief Scientific Officer
|
|
|
|
Summary ToggleTherapeuticsMD to present at 25th annual Piper Jaffray Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD applauds congressional leadership on passage of Drug Quality and Security Act
|
|
|
|
Summary ToggleTherapeuticsMD reports third quarter 2013 financial results
|
|
|
|
Summary ToggleVVA Phase 1 Results
|
|
|
|
Summary ToggleTherapeuticsMD appoints Sebastian Mirkin, M.D. as Chief Medical Officer
|
|
|
|
Summary ToggleTherapeuticsMD Third Quarter Results Conference Call
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. poster wins first-place prize at the North American Menopause Society 2013 Annual Meeting
|
|
|
|
Summary TogglePhase 1 data on first oral combination 17β-Estradiol and Progesterone capsule being developed for FDA review
|
|
|
|
Summary ToggleTherapeuticsMD to present at 12th Annual BIO Investor Forum
|
|
|
|
Summary ToggleTherapeuticsMD announces pricing of offering of common stock
|
|
|
|
Summary ToggleTherapeuticsMD begins patient enrollment in pivotal phase 3 clinical trial of TX-001HR
|
|
|
|
Summary ToggleTherapeuticsMD to present at STIFEL NICOLAUS 2013 Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD Initiates Phase 1 Study Of Estradiol Vagicap™
|
|
|
|
Summary ToggleTherapeuticsMD Reports 2nd Quarter 2013 Financial Results
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. Added to 2013 Russell Indexes
|
|
|
|
Summary ToggleTherapeuticsMD to Present at JMP Securities Healthcare Conference
|
|
|
|
Summary ToggleTherapeuticsMD Investigational New Drug Filing Accepted By FDA
|
|
|
|
Summary ToggleTherapeuticsMD to Ring Opening Bell at NYSE
|
|
|
|
Summary ToggleTherapeuticsMD To Present Jefferies Conference
|
|
|
|
Summary ToggleTherapeuticsMD elects Jules A. Musing to Board of Directors
|
|
|
|
Summary ToggleTherapeuticsMD reports first quarter 2013 financial results
|
|
|
|
Summary ToggleTherapeuticsMD Announces Trading of its Common Stock on the NYSE MKT under symbol "TXMD"
|
|
|
|
Summary ToggleTherapeuticsMD Announces Pricing of Public Offering of Common Stock
|
|
|
|
Summary ToggleTherapeuticsMD announces $50,000,000 proposed public offering of common stock
|
|
|
|
Summary ToggleBocaGreenMD Inc. launches line of generic prescription prenatal multivitamins
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. Announces $8.5 Million Private Placement
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. Has IND Filing Accepted By FDA
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. Launches vitaMedMD™ Iron 21/7, a Unique, Patient-friendly Iron Supplement
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. Announces Plans in Hormone Therapy That Concur with the Recent Joint Statement From NAMS, ASRM and the Endocrine Society
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. Files for Two Additional Patents on Prescription Products For Treatment of Menopausal Symptoms & Related Conditions
|
|
|
|
Summary ToggleTommy G. Thompson, Former U.S. Secretary of Health and Human Services, Joins TherapeuticsMD, Inc. as Chairman
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. Launches VitaMedMD RediChew Rx, The First Daily Chewable Prescription Prenatal Vitamin with Quatrefolic
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. Launches VitaMedMD One Rx, The First Daily One Pill Prescription Prenatal Vitamin with Quatrefolic and Plant-Based DHA
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. Launches VitaMedMD Plus Rx, The First Prescription Prenatal Vitamin with Quatrefolic and Plant-Based DHA
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. Elects Four Additional Directors
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. Launches Its First Prescription Prenatal Vitamin on March 1, 2012
|
|
|
|
Summary ToggleTherapeuticsMD, Inc. Acquires VitaMedMD, LLC
|
|
.jpg)
